Federal health officials have declined to approve the psychedelic drug MDMA as a therapy for PTSD. Drugmaker Lykos ...

The US Food and Drug Administration's (FDA) decision not to approve midomafetamine-assisted therapy (MDMA-AT) for ...

Lykos Therapeutics filed an application for FDA approval of its version of MDMA-assisted therapy for PTSD in February 2024.

In a previous blog on the use of psychedelics to treat mental health disorders, we reported that the US Food and Drug Administration (FDA) ...

Critics addressed the elephant in the room during the FDA’s first public meeting on trauma since its decision to delay ...

The FDA rejected MDMA therapy as a treatment for PTSD, with the advisory committee saying there is not enough evidence it was safe or effective. A setback to the use of psychedelics for the treatment ...

A Food and Drug Administration (FDA) advisory panel overwhelmingly rejected MDMA-assisted therapy for treating post-traumatic ...

Delve into the psychedelic-assisted therapy market and investors' sentiment after the FDA's decision about Lykos' MDMA ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

The departure of Amy Emerson as CEO comes three weeks after the MDMA developer revealed plans to cut 75% of its staff.

The Heroic Hearts Project, a nonprofit organization supporting veterans, reports that FDA-approved treatments are effective for fewer than 10% of veterans with PTSD. In contrast ... is projected for ...

Growing awareness of how addiction and trauma are intertwined has birthed a new generation of treatment strategies.